

# Fredrik Y Frejd

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11037450/publications.pdf>

Version: 2024-02-01

38  
papers

1,821  
citations

257450

24  
h-index

330143

37  
g-index

40  
all docs

40  
docs citations

40  
times ranked

2026  
citing authors

#	ARTICLE	IF	CITATIONS
1	Inhibition of IL17A Using an Affibody Molecule Attenuates Inflammation in ApoE-Deficient Mice. <i>Frontiers in Cardiovascular Medicine</i> , 2022, 9, 831039.	2.4	0
2	Abstract P3-02-06: A phase II study of <sup>68</sup> Ga-ABY-025 PET for non-invasive quantification of HER2 expression in breast cancer. <i>Cancer Research</i> , 2022, 82, P3-02-06-P3-02-06.	0.9	1
3	In Vitro Characterization of <sup>177</sup> Lu-DOTA-M5A Anti-Carcinoembryonic Antigen Humanized Antibody and HSP90 Inhibition for Potentiated Radioimmunotherapy of Colorectal Cancer. <i>Frontiers in Oncology</i> , 2022, 12, 849338.	2.8	3
4	Experimental Therapy of HER2-Expressing Xenografts Using the Second-Generation HER2-Targeting Affibody Molecule <sup>188</sup> Re-ZHER2:41071. <i>Pharmaceutics</i> , 2022, 14, 1092.	4.5	5
5	Bisppecific Antibody Molecule Inhibits Tumor Cell Proliferation More Efficiently Than the Two-Molecule Combination. <i>Drugs in R and D</i> , 2021, 21, 157-168.	2.2	9
6	Preclinical Evaluation of <sup>99m</sup> Tc-ZHER2:41071, a Second-Generation Affibody-Based HER2-Visualizing Imaging Probe with a Low Renal Uptake. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2770.	4.1	14
7	Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody <sup>®</sup> Molecules <sup>177</sup> Lu-ABY-271 and <sup>177</sup> Lu-ABY-027: Impact of DOTA Position on ABD Domain. <i>Pharmaceutics</i> , 2021, 13, 839.	4.5	5
8	Kinetic analysis of HER2-binding ABY-025 Affibody molecule using dynamic PET in patients with metastatic breast cancer. <i>EJNMMI Research</i> , 2020, 10, 21.	2.5	11
9	Imaging using radiolabelled targeted proteins: radioimmunodetection and beyond. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2020, 5, 16.	3.9	38
10	Affibody-Mediated Sequestration of Amyloid $\beta^2$ Demonstrates Preventive Efficacy in a Transgenic Alzheimer's Disease Mouse Model. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 64.	3.4	16
11	Comparative evaluation of affibody- and antibody fragments-based CAIX imaging probes in mice bearing renal cell carcinoma xenografts. <i>Scientific Reports</i> , 2019, 9, 14907.	3.3	14
12	CAIX-targeting radiotracers for hypoxia imaging in head and neck cancer models. <i>Scientific Reports</i> , 2019, 9, 18898.	3.3	22
13	In vivo depletion of serum IgG by an affibody molecule binding the neonatal Fc receptor. <i>Scientific Reports</i> , 2018, 8, 5141.	3.3	32
14	Same-Day Imaging Using Small Proteins: Clinical Experience and Translational Prospects in Oncology. <i>Journal of Nuclear Medicine</i> , 2018, 59, 885-891.	5.0	101
15	Evaluation of the Therapeutic Potential of a HER3-Binding Affibody Construct TAM-HER3 in Comparison with a Monoclonal Antibody, Seribantumab. <i>Molecular Pharmaceutics</i> , 2018, 15, 3394-3403.	4.6	19
16	In vivo evaluation of a novel format of a bivalent HER3-targeting and albumin-binding therapeutic affibody construct. <i>Scientific Reports</i> , 2017, 7, 43118.	3.3	20
17	Affibody Molecules in Biotechnological and Medical Applications. <i>Trends in Biotechnology</i> , 2017, 35, 691-712.	9.3	259
18	In Vivo Imaging of the Programmed Death Ligand 1 by <sup>18</sup> F PET. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1852-1857.	5.0	84

#	ARTICLE	IF	CITATIONS
19	Affibody molecules as engineered protein drugs. <i>Experimental and Molecular Medicine</i> , 2017, 49, e306-e306.	7.7	155
20	Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds. <i>MAbs</i> , 2016, 8, 1195-1209.	5.2	37
21	Comparative Evaluation of Affibody Molecules for Radionuclide Imaging of in Vivo Expression of Carbonic Anhydrase IX. <i>Molecular Pharmaceutics</i> , 2016, 13, 3676-3687.	4.6	30
22	Target-specific cytotoxic effects on HER2-expressing cells by the tripartite fusion toxin ZHER2:2891-ABD-PE38X8, including a targeting affibody molecule and a half-life extension domain. <i>International Journal of Oncology</i> , 2015, 47, 601-609.	3.3	21
23	An engineered affibody molecule with pH-dependent binding to FcRn mediates extended circulatory half-life of a fusion protein. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 17110-17115.	7.1	43
24	Engineering of a bispecific affibody molecule towards HER2 and HER3 by addition of an albumin-binding domain allows for affinity purification and in vivo half-life extension. <i>Biotechnology Journal</i> , 2014, 9, 1215-1222.	3.5	46
25	Imaging of Platelet-Derived Growth Factor Receptor $\beta^2$ Expression in Glioblastoma Xenografts Using Affibody Molecule <sup>111</sup> In-DOTA-Z09591. <i>Journal of Nuclear Medicine</i> , 2014, 55, 294-300.	5.0	50
26	Simultaneous targeting of two ligand-binding sites on VEGFR2 using biparatopic Affibody molecules results in dramatically improved affinity. <i>Scientific Reports</i> , 2014, 4, 7518.	3.3	31
27	Site-Specific Radiometal Labeling and Improved Biodistribution Using ABY-027, A Novel HER2-Targeting Affibody Molecule-Albumin-Binding Domain Fusion Protein. <i>Journal of Nuclear Medicine</i> , 2013, 54, 961-968.	5.0	75
28	Inhibiting HER3-Mediated Tumor Cell Growth with Affibody Molecules Engineered to Low Picomolar Affinity by Position-Directed Error-Prone PCR-Like Diversification. <i>PLoS ONE</i> , 2013, 8, e62791.	2.5	61
29	Generation and Evaluation of Bispecific Affibody Molecules for Simultaneous Targeting of EGFR and HER2. <i>Bioconjugate Chemistry</i> , 2012, 23, 1802-1811.	3.6	26
30	Cellular Effects of HER3-Specific Affibody Molecules. <i>PLoS ONE</i> , 2012, 7, e40023.	2.5	39
31	Non-immunoglobulin based protein scaffolds. <i>Current Opinion in Biotechnology</i> , 2011, 22, 843-848.	6.6	128
32	Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. <i>Protein Engineering, Design and Selection</i> , 2011, 24, 385-396.	2.1	62
33	Quantification of internalization of EGFR-binding Affibody molecules: Methodological aspects. <i>International Journal of Oncology</i> , 2010, 36, 757-63.	3.3	49
34	Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry. <i>Journal of Nuclear Medicine</i> , 2009, 50, 274-283.	5.0	98
35	Influence of valency and labelling chemistry on in vivo targeting using radioiodinated HER2-binding Affibody molecules. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 692-701.	6.4	54
36	Generation of tumour necrosis factor- $\alpha$ -specific affibody molecules capable of blocking receptor binding <i>in vitro</i> . <i>Biotechnology and Applied Biochemistry</i> , 2009, 54, 93-103.	3.1	33

#	ARTICLE	IF	CITATIONS
37	Engineering and characterization of a bispecific HER2-EGFR-binding affibody molecule. <i>Biotechnology and Applied Biochemistry</i> , 2009, 54, 121-131.	3.1	58
38	Targeting of Epidermal Growth Factor Receptor (EGFR)-Expressing Tumor Cells with Sterically Stabilized Affibody Liposomes (SAL). <i>Bioconjugate Chemistry</i> , 2009, 20, 1201-1208.	3.6	54